Journal of Bioanalysis & Biomedicine

Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

Publications

• Mini Review   
  Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine
  Author(s): Matthew Banerji*
  
  Chronic Lymphocytic Leukemia (CLL) is a common hematologic malignancy characterized by the accumulation of mature B lymphocytes in the blood, bone marrow, and lymphoid tissues. Historically, the backbone of CLL therapy has been fludarabine-based regimens for fit patients. However, the landscape of CLL treatment has transformed with the emergence of targeted agents, such as B-cell receptor signaling inhibitors and BCL-2 inhibitors. This article reviews the impact of targeted agents on the survival outcomes of CLL patients who are deemed fit for fludarabinebased therapy. It examines clinical trials, real-world evidence, and expert opinions to provide insights into the evolving treatment paradigms and the implications for clinical practice... Read More»
  DOI: 10.37421/1948-593X.2024.16.422

  Abstract HTML PDF